Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCAG versus DA for newly diagnosed elderly acute myeloid leukemia
ChiCTR-IIR-16008809Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of homoharringtonine, aclarubicin, cytarabine, granulocyte colony-stimulating factor and daunorubicin in acute myeloid leukemia (AML) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: Complete remission rate, Partial remission rate and 3 more. Started Jan 2014; status: recruiting.
02
Drugs
homoharringtonineaclarubicincytarabinegranulocyte colony-stimulating factordaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IIR-16008809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008809.